Medical devices, healthcare technology and the business of care
PMA approval · P210026

Ki-67 IHC pharmDx

Agilent Technologies, Inc. · Decision date Oct 12, 2021

FDA DECISIONP210026

What did the FDA approve?

FDA records P210026 as an original PMA application. The recorded decision is approval, dated Oct 12, 2021.

FDA approval order statement

Approval of Ki-67 IHC MIB-1 pharmDx (Dako Omnis)For In Vitro Diagnostic Use.Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is a qualitative immunohistochemical (IHC) assay using monoclonal mouse anti-Ki-67, Clone MIB-1, intended for use in the detection of Ki-67 protein in formalin-fixed, paraffin-embedded (FFPE) breast carcinoma tissue using the EnVision FLEX visualization system on Dako Omnis.Ki-67 protein expression in breast carcinoma is determined by using the Ki-67 pharmDx Score, which is the overall percentage of viable tumor cells in the invasive cancer component showing Ki-67 nuclear staining. The specimen should be considered to have Ki-67 expression if Ki-67 pharmDx Score is ? 20.Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is indicated as an aid in identifying patients with early breast cancer at high risk of disease recurrence for whom adjuvant treatment with Verzenio (abemaciclib) in combination with endocrine therapy is being considered.
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
Oct 12, 2021

FDA source record

Regulatory record facts

Identifier
P210026
Regulatory pathway
Premarket approval application
Product code
QQT
Decision code
APPR
Decision date
Oct 12, 2021
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry assay, antibody, Ki-67.

Product code
QQT
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P210026 received

    Application receipt date recorded by FDA.

  2. P210026 · FDA decision

    APPR

  3. P210026/S003 · Related supplement

    Ki-67 IHC MIB-1 pharmDx (Dako Omnis)

Timeline entries are records held by MedtechLedger for P210026. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210026

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA supplementSep 11, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Agilent Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5301 Stevens Creek Blvd., Santa Clara, CA, 95051

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records